Kodiak Sciences Inc. (Nasdaq: KOD) announced that the first patients have been enrolled in its global Phase 3 ALTO trial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE